FDA accepts Teva's application for Uzedy for bipolar I disorder
The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...
FDA accepts Teva & Medincell’s UZEDY sNDA for extended-release to treat BP-I
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
Teva targets schizophrenia to build on innovative medicines growth
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
Teva, Medincell announce FDA acceptance of sNDA for Uzedy
Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...
Pharmabiz5d
Teva Pharma, Medincell announce US FDA acceptance of sNDA for Uzedy to treat people living with schizophrenia
Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...
The Pharma Letter6d
FDA accepts Teva and Medincell’s Uzedy sNDA
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...
Pharm Exec21d
The Teva Turnaround: Steering a Company Comeback
Other factors he attributed for the lower profit guidance included the immediate hit this year to Teva’s schizophrenia drug, Uzedy, from the Medicare Part D redesign under the Inflation Reduction Act; ...
Seeking Alpha4d
TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops ... associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder ...
Nasdaq5d
Teva And Medincell Announce FDA Acceptance Of SNDA For UZEDY As Treatment For Bipolar I Disorder
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) and Medincell (MEDCL) announced that the FDA has accepted their supplemental New Drug Application, or sNDA, for UZEDY extended-release ...
Pharm Exec5d
FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Investing6d
FDA accepts Teva, Medincell's supplemental application for UZEDY as bipolar I disorder treatment
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...